Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.64 |
| ▸ | CTSB | P07858 | 2/20 | 0.64 |
| ▸ | CTSS | P25774 | 2/20 | 0.64 |
| ▸ | CTSK | P43235 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | TACR1 | P25103 | 3/20 | 0.62 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.58 |
| ▸ | TYR | P14679 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440666 | 1.00 | CTSL (0.64) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL29480462 | 0.95 | CTSL (0.66) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL11199738 | 0.95 | CTSL (0.62) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL6898524 | 0.94 | TACR1 (0.62) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL10964365 | 0.93 | MMP8 (0.56) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL5887348 | 0.92 | CTSL (0.57) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL5887352 | 0.92 | CTSL (0.57) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL2857463 | 0.92 | CTSL (0.57) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL5887289 | 0.92 | CTSL (0.57) | CTSLCTSBCTSSCTSKALDH1A1 | |
| SCHEMBL2857464 | 0.92 | CTSL (0.57) | CTSLCTSBCTSSCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924397-B2 | Process for the preparation of α-chloroketones from alkyl esters | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-20050090670-A1 | PROCESS FOR THE PREPARATION OF ALPHA-CHLOROKETONES FROM ALKYL ESTERS | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-28 | — | — | US | disclosed |
| EP-0156279-B1 | A NOVEL PROCESS FOR THE PREPARATION OF BESTATIN DERIVATIVES AND INTERMEDIATES THEREOF | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1989-09-13 | — | — | EP | disclosed |
| EP-0156279-A2 | A novel process for the preparation of bestatin derivatives and intermediates thereof | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090670-A1 | PROCESS FOR THE PREPARATION OF ALPHA-CHLOROKETONES FROM ALKYL ESTERS | KHK, BCKDK, STS | CTSL 418/4885CTSB 771/4885CTSS 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.